ORAMED PHARMACEUTICALS INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ORAMED PHARMACEUTICALS INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $4.01M, a 236.04% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $361.00K.
- ORAMED PHARMACEUTICALS INC. payments for repurchase of common stock for the quarter ending 2024-12-31 was $1.19M.
- ORAMED PHARMACEUTICALS INC. payments for repurchase of common stock for fiscal 2025 was $4.74M, a 90.86% increase from fiscal 2024.
- ORAMED PHARMACEUTICALS INC. payments for repurchase of common stock for fiscal 2024 was $2.48M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2025-12-31 | $4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.74M 10-K · filed 2026-03-26 |
| 2025-09-30 | $361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2024-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.48M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |